查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1957332

Calcium Channel Blockers Market - Global Industry Size, Share, Trends, Opportunity, & Forecast, Segmented By Drug Type, By Application, By Distribution Channel, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 180 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球鈣離子通道阻斷劑市場預計將從 2025 年的 162.2 億美元成長到 2031 年的 233.9 億美元，複合年成長率為 6.29%。

這些藥物透過抑制鈣離子流入心肌細胞和動脈細胞，促進血管舒張，進而改善心臟的氧氣輸送。市場成長的主要促進因素並非固定劑量複方製劑等短期趨勢，而是慢性心血管疾病在全球日益加重的負擔以及人口快速老化導致持續治療管理需求不斷增加。

市場概覽
預測期 2027-2031
市場規模：2025年 162.2億美元
市場規模：2031年 233.9億美元
複合年成長率：2026-2031年 6.29%
成長最快的細分市場 二氫吡啶（DHP）
最大的市場 北美洲

儘管臨床需求強勁，但主要品牌藥專利到期卻構成了一項重大障礙：價格低廉的學名藥正在蠶食品牌藥的收入來源。這種競爭壓力阻礙了品牌藥的財務擴張，儘管患者數量仍在持續成長。世界衛生組織（世衛組織）2025年發布的數據顯示，到2024年，全球約有14億人將患有高血壓，凸顯了該疾病的巨大規模，亟需有效的治療方案。

市場促進因素

全球高血壓和心血管疾病盛行率的激增是鈣離子通道阻斷劑市場的主要促進因素，也因此產生了對降血壓藥物治療的迫切需求。隨著這些疾病成為主要致病原因，醫療系統優先使用氨氯地平等藥物來降低中風風險，導致處方量增加，對現有療法的需求持續強勁。根據美國心臟協會 (AHA) 於 2025 年 1 月發布的《2025 年心血管和中風統計更新》，心血管疾病預計將導致全球約 1941 萬人死亡，凸顯了有效管理的重要性。此外，根據英國國家醫療服務體系 (NHS) 商業服務部門 2025 年 6 月報告，2024/25 年度氨氯地平的處方量為 3,970 萬劑，仍然是英格蘭處方量最大的藥物之一。

由於老年人口的快速成長，市場成長正在進一步加速，因為老齡化與動脈粥狀硬化和單純收縮期高血壓的進展密切相關。這種人口結構的變化需要長期持續用藥，而老年人，尤其是在平均預期壽命不斷延長的已開發地區，併發症風險較高，因此他們成為這些藥物的主要消費群體。根據內務部2025年9月發布的公告，日本65歲以上人口占總人口的比例已達到創紀錄的29.4%。这表明需要接受心血管疾病治疗的人群规模正在扩大。

市場挑戰

主要品牌藥專利的到期對全球鈣離子通道阻斷劑市場構成重大障礙，直接限制了其財務成長。一旦獨家經銷權到期，低成本學名藥將大幅蠶食市場佔有率，削弱生產商的定價權，並導致現有重磅療法的收入急劇下降。因此，學名藥的湧入使治療領域趨於同質化，降低了製藥公司的利潤率，使得整體市場估值難以與臨床需求保持同步成長。

高血壓的高發生率進一步加劇了收入下滑。雖然高發病率顯著增加了處方箋量，但單位藥品收入卻呈下降趨勢。根據美國心臟協會 (AHA) 2025 年的預測，屆時美國約有 50% 的成年人將患有高血壓。這些數據表明，儘管患者群體龐大，但由於大部分需求由低價學名藥滿足，而對高價值品牌藥的需求有限，市場收入成長受到抑制。

市場趨勢

隨著醫療機構優先考慮簡化治療方法以提高患者依從性，固定劑量組合藥物的日益普及正在改變市場格局。這一趨勢包括將鈣通道阻斷劑和其他降血壓藥物組合成單片製劑的開發，旨在減輕用藥負擔並改善臨床療效。用於治療早期高血壓的三重組合藥物的推出就是一個例子。根據 Medscape Medical News 2025 年 6 月報道，美國食品藥物管理局(FDA)核准了一種新的固定劑量組合藥物，該藥物由氨氯地平、Telmisartan和吲達帕胺組成，詳情見題為“FDA核准用於治療高血壓的三聯組合藥物”的報導。該藥物有三種劑量規格，以滿足患者的不同需求。

同時，學名藥的快速上市正在加速市場活動。各公司正利用專利到期推出更具成本效益的替代藥物。這一趨勢導致簡略新藥申請（ANDA）的提交和核准激增，顯著擴大了現有鈣離子通道阻斷劑療法的可及性。這是因為各公司正積極透過非專利版本來強化其產品線。例如，根據《商業標準報》2025年8月報道，Zydus Life Sciences公司用於治療心絞痛的鹽酸地爾硫卓片獲得了美國食品藥物管理局（FDA）的最終核准。該藥物瞄準了美國一個年銷售額約1390萬美元的特定細分市場。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：全球鈣離子通道阻斷劑市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 藥物類型（二氫吡啶類、苯烷基胺類、苯並噻唑類）
    • 依應用領域（心絞痛、高血壓、肥厚型心肌病、心律不整等）
    • 分銷通路（網路藥局、醫院藥局、零售藥局）
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

第6章：北美鈣離子通道阻斷劑市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國別分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲鈣離子通道阻斷劑市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國別分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太地區鈣離子通道阻斷劑市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國別分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：中東和非洲鈣離子通道阻斷劑市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東與非洲：國別分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美鈣離子通道阻斷劑市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國別分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進因素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 近期趨勢

第13章：全球鈣離子通道阻斷劑市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的議價能力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • Bayer AG
  • Sanofi Sa
  • Pfizer Inc
  • Lupin Pharmaceuticals, Inc.
  • Searle Ltd
  • Knoll Pharmaceuticals Co
  • GlaxoSmithKline Plc.
  • Aventis Inc
  • AstraZeneca PLC
  • Novartis AG

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 17248

The Global Calcium Channel Blockers Market is projected to expand from USD 16.22 Billion in 2025 to USD 23.39 Billion by 2031, reflecting a compound annual growth rate of 6.29%. These pharmaceutical agents function by inhibiting the influx of calcium into cardiac and arterial cells, which facilitates blood vessel relaxation and enhances oxygen delivery to the heart. The market's growth is fundamentally supported by the rising global burden of chronic cardiovascular diseases and a rapidly aging population requiring consistent therapeutic management, drivers that are distinct from transient trends such as the shift toward fixed-dose combination therapies.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 16.22 Billion
Market Size 2031USD 23.39 Billion
CAGR 2026-20316.29%
Fastest Growing SegmentDihydropyridine (DHP)
Largest MarketNorth America

Despite robust clinical demand, the market encounters significant obstacles due to the expiration of patents for major branded drugs, enabling affordable generic alternatives to diminish branded revenue streams. This competitive pressure constrains financial expansion even as the patient population continues to increase. According to the World Health Organization, data released in 2025 indicated that approximately 1.4 billion individuals globally were living with hypertension in 2024, highlighting the massive scale of the condition that necessitates effective treatment solutions.

Market Driver

The surging global prevalence of hypertension and cardiovascular diseases serves as the primary catalyst for the calcium channel blockers market, creating an urgent need for antihypertensive pharmacotherapy. As these conditions become leading causes of morbidity, healthcare systems are prioritizing agents like amlodipine to lower stroke risks, resulting in elevated prescription volumes and sustained demand for established therapeutics. According to the American Heart Association's '2025 Heart Disease and Stroke Statistics Update' from January 2025, cardiovascular disease caused approximately 19.41 million deaths globally, emphasizing the critical need for effective management; furthermore, the NHS Business Services Authority reported in June 2025 that amlodipine remained a top prescribed medicine in England with 39.7 million items dispensed during 2024/25.

Market growth is further amplified by the rapid expansion of the geriatric population, as aging is intrinsically linked to increased arterial stiffness and isolated systolic hypertension. This demographic shift requires consistent, long-term medication regimens, positioning the elderly as the primary consumer base for these drugs, particularly given their susceptibility to comorbidities in developed regions with rising life expectancies. According to the Ministry of Internal Affairs and Communications of Japan in September 2025, the elderly population aged 65 and over reached a record 29.4% of the nation's total, demonstrating the expanding scale of the demographic requiring cardiovascular interventions.

Market Challenge

The expiration of patents for key branded drugs presents a substantial hurdle that directly restricts the financial growth of the Global Calcium Channel Blockers Market. When exclusive marketing rights cease, lower-cost generic alternatives seize significant market share, forcing a reduction in pricing power for manufacturers and leading to a sharp decline in revenue from established blockbuster therapies. Consequently, the overall market valuation struggles to grow at the same pace as clinical demand, as the influx of generics commoditizes the treatment landscape and erodes profit margins for original innovators.

This revenue erosion is exacerbated by the high prevalence of the condition, which generates substantial prescription volumes but yields diminishing returns per unit. According to the American Heart Association in 2025, nearly 50% of adults in the United States were estimated to have high blood pressure. This data highlights that while the patient base is extensive, the market's financial trajectory is suppressed because a significant portion of this demand is satisfied by low-cost generic agents rather than high-value branded formulations.

Market Trends

The increasing adoption of fixed-dose combination therapies is reshaping the market as healthcare providers prioritize simplified treatment regimens to enhance patient adherence. This trend involves the development of single-pill formulations that merge calcium channel blockers with other antihypertensive agents, thereby reducing pill burden and improving clinical outcomes, including the introduction of triple-combination therapies for initial hypertension treatment. According to Medscape Medical News in June 2025, the US FDA approved a novel fixed-dose combination of amlodipine, telmisartan, and indapamide, available in three dosage strengths to accommodate varying patient needs, as detailed in the article 'FDA Approves Triple Rx for Hypertension'.

Simultaneously, the accelerated commercialization of generic drug variants is intensifying market activity as manufacturers leverage patent expirations to introduce cost-effective alternatives. This trend is driving a surge in Abbreviated New Drug Application (ANDA) filings and approvals, significantly broadening access to established calcium channel blocker therapies as companies aggressively fortify their portfolios with generic versions. For instance, according to Business Standard in August 2025, Zydus Lifesciences received final USFDA approval for Diltiazem Hydrochloride tablets to treat angina, targeting a specific market segment that generated annual sales of approximately $13.9 million in the United States.

Key Market Players

  • Bayer AG
  • Sanofi Sa
  • Pfizer Inc
  • Lupin Pharmaceuticals, Inc.
  • Searle Ltd
  • Knoll Pharmaceuticals Co
  • GlaxoSmithKline Plc.
  • Aventis Inc
  • AstraZeneca PLC
  • Novartis AG

Report Scope

In this report, the Global Calcium Channel Blockers Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Calcium Channel Blockers Market, By Drug Type

  • Dihydropyridine
  • Phenylalkylamine
  • Benzothizepine

Calcium Channel Blockers Market, By Application

  • Angina
  • Hypertension
  • Hypertrophic Cardiomyopathy
  • Arrhythmia
  • Others

Calcium Channel Blockers Market, By Distribution Channel

  • Online Pharmacies
  • Hospital Pharmacies
  • Retail Pharmacies

Calcium Channel Blockers Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Calcium Channel Blockers Market.

Available Customizations:

Global Calcium Channel Blockers Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Calcium Channel Blockers Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Drug Type (Dihydropyridine, Phenylalkylamine, Benzothizepine)
    • 5.2.2. By Application (Angina, Hypertension, Hypertrophic Cardiomyopathy, Arrhythmia, Others)
    • 5.2.3. By Distribution Channel (Online Pharmacies, Hospital Pharmacies, Retail Pharmacies)
    • 5.2.4. By Region
    • 5.2.5. By Company (2025)
  • 5.3. Market Map

6. North America Calcium Channel Blockers Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Drug Type
    • 6.2.2. By Application
    • 6.2.3. By Distribution Channel
    • 6.2.4. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Calcium Channel Blockers Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Drug Type
        • 6.3.1.2.2. By Application
        • 6.3.1.2.3. By Distribution Channel
    • 6.3.2. Canada Calcium Channel Blockers Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Drug Type
        • 6.3.2.2.2. By Application
        • 6.3.2.2.3. By Distribution Channel
    • 6.3.3. Mexico Calcium Channel Blockers Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Drug Type
        • 6.3.3.2.2. By Application
        • 6.3.3.2.3. By Distribution Channel

7. Europe Calcium Channel Blockers Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Drug Type
    • 7.2.2. By Application
    • 7.2.3. By Distribution Channel
    • 7.2.4. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Calcium Channel Blockers Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Drug Type
        • 7.3.1.2.2. By Application
        • 7.3.1.2.3. By Distribution Channel
    • 7.3.2. France Calcium Channel Blockers Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Drug Type
        • 7.3.2.2.2. By Application
        • 7.3.2.2.3. By Distribution Channel
    • 7.3.3. United Kingdom Calcium Channel Blockers Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Drug Type
        • 7.3.3.2.2. By Application
        • 7.3.3.2.3. By Distribution Channel
    • 7.3.4. Italy Calcium Channel Blockers Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Drug Type
        • 7.3.4.2.2. By Application
        • 7.3.4.2.3. By Distribution Channel
    • 7.3.5. Spain Calcium Channel Blockers Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Drug Type
        • 7.3.5.2.2. By Application
        • 7.3.5.2.3. By Distribution Channel

8. Asia Pacific Calcium Channel Blockers Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Drug Type
    • 8.2.2. By Application
    • 8.2.3. By Distribution Channel
    • 8.2.4. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Calcium Channel Blockers Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Drug Type
        • 8.3.1.2.2. By Application
        • 8.3.1.2.3. By Distribution Channel
    • 8.3.2. India Calcium Channel Blockers Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Drug Type
        • 8.3.2.2.2. By Application
        • 8.3.2.2.3. By Distribution Channel
    • 8.3.3. Japan Calcium Channel Blockers Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Drug Type
        • 8.3.3.2.2. By Application
        • 8.3.3.2.3. By Distribution Channel
    • 8.3.4. South Korea Calcium Channel Blockers Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Drug Type
        • 8.3.4.2.2. By Application
        • 8.3.4.2.3. By Distribution Channel
    • 8.3.5. Australia Calcium Channel Blockers Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Drug Type
        • 8.3.5.2.2. By Application
        • 8.3.5.2.3. By Distribution Channel

9. Middle East & Africa Calcium Channel Blockers Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Drug Type
    • 9.2.2. By Application
    • 9.2.3. By Distribution Channel
    • 9.2.4. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Calcium Channel Blockers Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Drug Type
        • 9.3.1.2.2. By Application
        • 9.3.1.2.3. By Distribution Channel
    • 9.3.2. UAE Calcium Channel Blockers Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Drug Type
        • 9.3.2.2.2. By Application
        • 9.3.2.2.3. By Distribution Channel
    • 9.3.3. South Africa Calcium Channel Blockers Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Drug Type
        • 9.3.3.2.2. By Application
        • 9.3.3.2.3. By Distribution Channel

10. South America Calcium Channel Blockers Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Drug Type
    • 10.2.2. By Application
    • 10.2.3. By Distribution Channel
    • 10.2.4. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Calcium Channel Blockers Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Drug Type
        • 10.3.1.2.2. By Application
        • 10.3.1.2.3. By Distribution Channel
    • 10.3.2. Colombia Calcium Channel Blockers Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Drug Type
        • 10.3.2.2.2. By Application
        • 10.3.2.2.3. By Distribution Channel
    • 10.3.3. Argentina Calcium Channel Blockers Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Drug Type
        • 10.3.3.2.2. By Application
        • 10.3.3.2.3. By Distribution Channel

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Calcium Channel Blockers Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Bayer AG
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Sanofi Sa
  • 15.3. Pfizer Inc
  • 15.4. Lupin Pharmaceuticals, Inc.
  • 15.5. Searle Ltd
  • 15.6. Knoll Pharmaceuticals Co
  • 15.7. GlaxoSmithKline Plc.
  • 15.8. Aventis Inc
  • 15.9. AstraZeneca PLC
  • 15.10. Novartis AG

16. Strategic Recommendations

17. About Us & Disclaimer